Skip to main content
BEAT logo

BEAT · HeartBeam, Inc.

Track BEAT — free
$0.28 -0.03 (-8.90%)
Market Cap
$19.56M
Shares
63.31M
Volume · Nov 20 399.55K Avg daily vol (3M) 7.39M

Price & Indicators

 

Key stats

Close
$0.31
Thu 19 Nov
Open
$0.34
Thu 19 Nov
Average volume, 30 days
1.2M
shares a session
Short interest
2.3M
3.6% of shares · 1.6 days to cover
Day range
$0.30$0.35
Open $0.34 Close $0.31
52-week closing range
$0.31$3.44
Close $0.31 91.0% under the high
Short volume, last session
49%
Last earnings
Nov 12, 2026
Latest filing
10-Q · Nov 12
Price history
Nov 2021 to Nov 2026

Up next

Dec 30, 2026 Est · unconfirmed · in 6 wks

Latest documents

2026
Nov 12
Earnings call
FDA pathway supports accelerated pivotal study plan

HeartBeam aligned with the FDA on a 510k pathway, plans a pivotal study beginning in 2027, reported Q3 2026 operating cash use of $2.6 million, and had pro forma cash of approximately $10.1 million.

4 source passages
the alignment with the FDA on our 510k pathway, which is a super important step. Next in line is our US pivotal study planned, again, for beginning of 2027. Taking a look at the Q3 2026 financials, and we'll focus in on cash flow first. Net cash use and operating activities for $2.6 million in the quarter. So in total, that gives us a pro forma cash balance of approximately $10.1 million. Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
FDA grants heart attack assessment breakthrough designation

HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months.

Net loss $3.01M Diluted EPS -$0.05
Read from the MD&A section
5 source passages
On October 5, 2026, the Company received FDA Breakthrough Device Designation for Heart Attack Assessment. Positive results from the ALIGN-ACS pilot study were presented by Graham Nichol, MD, MPH, FRCP(C), of the University of Washington, at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 conference. HeartBeam’s 3D ECG technology was shown to be as accurate as the standard 12-Lead ECG. The device demonstrated higher specificity than standard 12-lead ECG (81.8% vs. 71.4%), with comparable sensitivity. On June 30, 2026, the Company received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that the closing bid price of its common stock had fallen below the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until December 28, 2026, to regain compliance. Based on our current business plan assumptions and expected cash burn rate, the Company believes that the existing cash is insufficient to fund operations for the next twelve months following the issuance of these financial statements. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$18.05M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-68.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$6.07M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+66.3%
Year over year · more shares
Price change (1Y)
-81.4%
Trailing year
Short interest
3.6%
Latest settlement · 1.6 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −60%
below
Price vs 50-day avg −27%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −22%
trailing
6-month return −65%
trailing
YTD return −87%
this year
Relative strength −59%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.58% of shares out · ▼ -8.6% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
44 holders — near 3-yr high, broad support
Squeeze score 45
elevated · 0–100
Fundamentals
Strong
EPS growth +15%
Y/Y
Free cash flow $-14.6M
Balance sheet $4.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 164%
annualized · 1-yr
Max drawdown −91%
past year
ATR 13.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 13, 2026
Operating cash outflows · full year 2026 up to $14M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−60% Bearish
Price vs 50-day avg
−27% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow Flat
0% holders QoQ · +4 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.58% of shares out · ▼ -8.6% MoM · 1.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
44 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $3
vs 200-day avg -60% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Health Information Services — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BEAT
HeartBeam, Inc.
this stock
$19.56M -87.1% — — 3.6%
VEEV
Veeva Systems Inc
$42.57B +17.8% +28.1% 43.0 2.4%
PMDIY
Pro Medicus Ltd.
$14.81B -14.6% — — 0.0%
BTSG
BrightSpring Health Services, Inc.
$12.74B +70.9% +28.2% 34.8 5.8%
TEM
Tempus AI, Inc.
$10.87B +0.9% +83.4% — 13.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
44
% held
13.7%
Net QoQ
-23.6K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
2.3M
Days to cover
1.6d
Change
-214.7K sh
View
Short Volume
Short vol %
49%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
41.3K
Value
$22.3K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
66.8%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-21.0M
EPS diluted
$-0.62
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
16

HeartBeam, Inc. received FDA Breakthrough Device Designation for heart attack assessment on October 5, 2026. ALIGN-ACS showed 81.8% specificity versus 71.4% for 12-lead ECG; Nasdaq compliance is due by December 28, 2026, and cash is insufficient for twelve months.

View
Earnings & Events
Webcasts
Last webcast
Nov 12, 2026
View
Investor Relations
Latest news
HeartBeam Reports Third Quarter 2…
Published
Nov 12, 2026
View

Performance

5D 20D 120D MTD YTD
BEAT -23.5% -22.4% -65.1% -43.8% -87.1%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -18.0% -16.1% -59.4% -38.6% -92.1%
Key facts CIK 1779372 13F (30d) 39 filings 36 filers Visit website Investor relations